SCHEMBL1340460

SCHEMBL1340460

Nc1ccccc1Oc1ccc(Cl)c(Cl)c1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
KDM4E B2RXH2 2/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
ALDH1A1 P00352 4/20 0.42
ADRA2B P18089 1/20 0.42
PTGS1 P23219 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GAA P10253 2/20 0.42
RCE1 Q9Y256 1/20 0.42
TSHR P16473 1/20 0.41
CYP1A2 P05177 4/20 0.41
CYP2C19 P33261 4/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 3/20 0.41
FABP3 P05413 1/20 0.38
RHEB Q15382 1/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
IKBKB O14920 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28360712 0.84 ALDH1A1 (0.46) MAPTKDM4ECRHBPCRHR2ALDH1A1
SCHEMBL11283671 0.81 CYP3A4 (0.43) MAPTALDH1A1TDP1TSHRCYP3A4
SCHEMBL9266509 0.79 TSHR (0.54) MAPTKDM4ECRHBPCRHR2ALDH1A1
SCHEMBL30379539 0.79 TSHR (0.54) MAPTKDM4ECRHBPCRHR2ALDH1A1
SCHEMBL30979203 0.78 KDM4E (0.65) MAPTKDM4ECRHBPCRHR2ALDH1A1
SCHEMBL81185 0.78 KDM4E (0.65) MAPTKDM4ECRHBPCRHR2ALDH1A1
SCHEMBL29508342 0.78 KDM4E (0.65) MAPTKDM4ECRHBPCRHR2ALDH1A1
SCHEMBL30290439 0.77 L3MBTL1 (0.50) MAPTALDH1A1ADRA2BPTGS1TDP1
SCHEMBL319832 0.77 CYP3A4 (0.45) MAPTALDH1A1GAATSHRCYP3A4
SCHEMBL5542851 0.77 RHEB (0.37) ALDH1A1CYP3A4FABP3RHEBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE45670-E1 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2015-09-15 US disclosed
EP-2471533-A1 Aryl carbonyl derivatives as therapeutic agents Novo Nordisk A/S (DK) 2012-07-04 EP disclosed
US-20110301158-A1 ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS NOVO NORDISK A/S (DK) 2011-12-08 US disclosed
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-7541373-B2 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2009-06-02 US disclosed
US-7384967-B2 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2008-06-10 US disclosed
US-20080119454-A1 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2008-05-22 US disclosed
US-20080119455-A1 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2008-05-22 US disclosed
US-20060183783-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2006-08-17 US disclosed
EP-1531815-A1 GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2005-05-25 EP disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed
WO-2004002481-A1 ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS NOVO NORDISK A/S (DK) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301158-A1 ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS GCK, GCKR, PDK2 MAPT 2678/4885KDM4E 992/4885CRHBP 3345/4885
US-20080119455-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 MAPT 2678/4885KDM4E 992/4885CRHBP 3345/4885
US-20060183783-A1 Aryl carbonyl derivatives as therapeutic agents GCK, PDK3, PDK4 MAPT 2678/4885KDM4E 1420/4885CRHBP 3117/4885
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 MAPT 2678/4885KDM4E 992/4885CRHBP 3345/4885
US-20080119454-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 MAPT 2678/4885KDM4E 992/4885CRHBP 3345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.